Protalix BioThera (PLX) May Have a Winner with Gaucher Drug prGCD
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics (AMEX: PLX) shares have skyrocketed over the past several months. Shares are up to a high of $11.30 from $4 in June, representing a gain of 182.5%.
According to a report from Businessweek, the company's main drug, prGCD showed favorable results in Phase II trials. The drug is a treatment for Gaucher's disease, which causes blood problems and enlargement of the liver and spleen.
An analyst from Oppenheimer rated the shares at Outperform, commenting that the company may find either a partner or buyer in a U.S. drugmaker. PrCGD would be a prime competitor with Genzyme's (NASDAQ: GENZ) Cerezyme. The method of producing enzymes for Protalix is fairly low-cost as well, adding additional appeal to the company.
According to a report from Businessweek, the company's main drug, prGCD showed favorable results in Phase II trials. The drug is a treatment for Gaucher's disease, which causes blood problems and enlargement of the liver and spleen.
An analyst from Oppenheimer rated the shares at Outperform, commenting that the company may find either a partner or buyer in a U.S. drugmaker. PrCGD would be a prime competitor with Genzyme's (NASDAQ: GENZ) Cerezyme. The method of producing enzymes for Protalix is fairly low-cost as well, adding additional appeal to the company.
You May Also Be Interested In
- Raymond James sees token pricing gap widen in August 2026
- BofA tracks building products sales momentum in second quarter
- Dollar stores see mixed outlook ahead of earnings next week, Gordon Haskett comments
Create E-mail Alert Related Categories
General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
